L-Nutra develops "Nutrition for Longevity" and "Nutrition as Medicine" programs that reformulate food into precise, science-backed interventions such as its Prolon dietary regimen. The company collaborates with 18 university research centers and supports its products with 47 clinical trials and 137 granted patents. Its offerings aim to add healthy years to life and drive remission in chronic illnesses by integrating nutrition into mainstream healthcare. Backed by blue-chip investors, L-Nutra is rapidly expanding its global footprint and has already introduced nutrition and education initiatives in seven Abu Dhabi schools. A newly announced joint venture with Mubadala will localize manufacturing of its medical and longevity nutrition products for the Middle East and North Africa. The business positions itself as the first “nutri-technology” firm, blending biotech rigor with food technology to address aging and disease. Following its latest capital infusion, L-Nutra has raised $83.5 million in Series D funding to fuel further R&D and international expansion.

Total raised

$84M

Funding rounds

2

Latest round

Series D

Latest activity

Jan 2026